[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Pro-Dex Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":127},{"warningLetters":4,"total":126},[5,31,58,80,104],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},22015,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-05T04:00:00Z\">10\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpro-optics-llc-734689-10052026\">Pro-Optics, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Eric A. Nyman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Pro-Optics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>317 N Woodwork Ln\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Palatine\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60067-4932\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 739966\u003C\u002Fp>\u003Cp>October 5, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Nyman:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Palatine, Illinois from March 3, 2026 through March 11, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tight Top Contact Lens Cases and Flip Top Contact Lens Cases. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003Cbr>Our inspection and review of your website, www.proopticsgroup.com, determined that the Tight Top contact lens case and the Flip Top contact lens case are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The Tight Top contact lens case and the Flip Top contact lens case are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because you did not notify the agency of your intent to introduce or deliver for introduction the devices into commercial distribution, in that a notice or other information respecting the modifications to the devices was not provided to the FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>A device that is currently in commercial distribution that has been significantly changed or modified in design, components, method of manufacture, or intended use requires a premarket notification submission; significant changes or modifications include a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process. 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>Specifically, you modified the Tight Top contact lens case and the Flip Top contact lens case, cleared under K875197, by changing the polymers and colorants used in their manufacturing. The materials currently used in the Tight Top contact lens case (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and the Flip Top contact lens case (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) represent a significant material deviation from the devices cleared under K875197, which specified the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). These are significant changes to the material of the devices that could significantly affect their safety or effectiveness.\u003C\u002Fp>\u003Cp>Furthermore, the clearance under K875197 specifies four colors: \u003Cstrong>(b)(4)\u003C\u002Fstrong> grey, \u003Cstrong>(b)(4)\u003C\u002Fstrong> white, \u003Cstrong>(b)(4)\u003C\u002Fstrong> blue, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> aqua. Your firm’s introduction of additional, uncleared colorants (including red, magenta, green, yellow, orange, orange, purple, and black) for the Tight Top contact lens case and the Flip Top contact lens case introduces unreviewed biocompatibility risks. These are significant changes to the chemical compositions of the devices that could significantly affect their safety or effectiveness.\u003C\u002Fp>\u003Cp>Because the FDA has not evaluated these material and colorant modifications, the safety and effectiveness of the redesigned Tight Top Contact Lens Cases and Flip Top Contact Lens Cases have not been established.\u003C\u002Fp>\u003Cp>\u003Cu>Quality Management System Regulation Violations\u003C\u002Fu>\u003Cbr>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to document procedures for design and development, as required by ISO 13485:2016, Clause 7.3.1. Specifically, your firm failed to document procedures for design and development, including design and development: inputs, outputs, review, verification, validation, transfer, and control of changes for the Pro Optics Tight Top and Flip Top Contact Lens Cases. For example,\u003C\u002Fp>\u003Cp>a) Your firm does not have documented design and development procedures. During the inspection, you acknowledged that your firm does not have documented design and development procedures and you could not provide required design and development records upon request.\u003Cbr>b) Your firm does not have documented design and development transfer procedures. During the FDA inspection you stated that your firm does \"not have documented evidence of proper transfer of design output information from the previous owner\" to manufacturing.\u003Cbr>c) The design modifications were not subject to control of design and development changes prior to implementation. During the inspection you stated that \"these design modifications were not subjected to the required review and approval processes prior to implementation.\" Your firm failed to document the control of design and development changes or evaluate the effect of these modifications on the finished device.\u003Cbr>d) Your firm has not maintained design and development output records, including design drawings. When these records were requested during the inspection, you stated, \"We don't have device drawings\" and indicated that you would \"document and maintain those for future inspections.\" Without maintained design and development output records constituting the medical device file, your firm cannot demonstrate that manufactured devices meet design specifications and design and development input requirements or intended use.\u003C\u002Fp>\u003Cp>Since January 1, 2024, your firm has manufactured approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> Pro Optics Tight Top Contact Lens Cases and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Flip Top Contact Lens Cases, for the storage, disinfection, and cleaning of contact lenses.\u003C\u002Fp>\u003Cp>2. Failure to control or evaluate changes to quality management system processes for their impact on the quality management system and on medical devices produced, as required by ISO 13485:2016, Clause 4.1.4. Specifically, your firm's Change Control Procedure (SOP 2.4, Section 5.0, Rev. 1.30, Eff. Date August 28, 2020) requires that \"changes to production processes are documented on the change control form.\" Your firm failed to document the change from contract manufacturer \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing via \u003Cstrong>(b)(4)\u003C\u002Fstrong> molding, which occurred on January 8, 2021. Furthermore, your firm did not evaluate the impact of this manufacturing change on the devices produced and the process controls necessary to address potential risks to product quality and end users. During the inspection you stated that \"an impact assessment was not conducted to evaluate effects on the quality management system and device quality.\"\u003C\u002Fp>\u003Cp>We are unable to determine the adequacy of your corrective actions as your firm has not provided a response to the observations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Melissa Michurski, Establishment Assessment Team 2, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case #739966” when replying. If you have any questions about the contents of this letter, please contact: Rafael Padilla, Compliance Officer at Rafael.Padilla@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nEric A. Nyman\n\nRecipient Title\n\nPresident and Co-Owner\n\nPro-Optics, LLC\n\n317 N Woodwork Ln\n\nPalatine, IL 60067-4932\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 739966\nOctober 5, 2026\nDear Mr. Nyman:\nDuring an inspection of your firm located in Palatine, Illinois from March 3, 2026 through March 11, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tight Top Contact Lens Cases and Flip Top Contact Lens Cases. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violations\nOur inspection and review of your website, www.proopticsgroup.com, determined that the Tight Top contact lens case and the Flip Top contact lens case are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The Tight Top contact lens case and the Flip Top contact lens case are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because you did not notify the agency of your intent to introduce or deliver for introduction the devices into commercial distribution, in that a notice or other information respecting the modifications to the devices was not provided to the FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81(a)(3)(i).\nA device that is currently in commercial distribution that has been significantly changed or modified in design, components, method of manufacture, or intended use requires a premarket notification submission; significant changes or modifications include a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process. 21 CFR 807.81(a)(3)(i).\nSpecifically, you modified the Tight Top contact lens case and the Flip Top contact lens case, cleared under K875197, by changing the polymers and colorants used in their manufacturing. The materials currently used in the Tight Top contact lens case ((b)(4)) and the Flip Top contact lens case ((b)(4)) represent a significant material deviation from the devices cleared under K875197, which specified the use of (b)(4) ((b)(4)). These are significant changes to the material of the devices that could significantly affect their safety or effectiveness.\nFurthermore, the clearance under K875197 specifies four colors: (b)(4) grey, (b)(4) white, (b)(4) blue, and (b)(4) aqua. Your firm’s introduction of additional, uncleared colorants (including red, magenta, green, yellow, orange, orange, purple, and black) for the Tight Top contact lens case and the Flip Top contact lens case introduces unreviewed biocompatibility risks. These are significant changes to the chemical compositions of the devices that could significantly affect their safety or effectiveness.\nBecause the FDA has not evaluated these material and colorant modifications, the safety and effectiveness of the redesigned Tight Top Contact Lens Cases and Flip Top Contact Lens Cases have not been established.\nQuality Management System Regulation Violations\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n1. Failure to document procedures for design and development, as required by ISO 13485:2016, Clause 7.3.1. Specifically, your firm failed to document procedures for design and development, including design and development: inputs, outputs, review, verification, validation, transfer, and control of changes for the Pro Optics Tight Top and Flip Top Contact Lens Cases. For example,\na) Your firm does not have documented design and development procedures. During the inspection, you acknowledged that your firm does not have documented design and development procedures and you could not provide required design and development records upon request.\nb) Your firm does not have documented design and development transfer procedures. During the FDA inspection you stated that your firm does \"not have documented evidence of proper transfer of design output information from the previous owner\" to manufacturing.\nc) The design modifications were not subject to control of design and development changes prior to implementation. During the inspection you stated that \"these design modifications were not subjected to the required review and approval processes prior to implementation.\" Your firm failed to document the control of design and development changes or evaluate the effect of these modifications on the finished device.\nd) Your firm has not maintained design and development output records, including design drawings. When these records were requested during the inspection, you stated, \"We don't have device drawings\" and indicated that you would \"document and maintain those for future inspections.\" Without maintained design and development output records constituting the medical device file, your firm cannot demonstrate that manufactured devices meet design specifications and design and development input requirements or intended use.\nSince January 1, 2024, your firm has manufactured approximately (b)(4) Pro Optics Tight Top Contact Lens Cases and (b)(4) Flip Top Contact Lens Cases, for the storage, disinfection, and cleaning of contact lenses.\n2. Failure to control or evaluate changes to quality management system processes for their impact on the quality management system and on medical devices produced, as required by ISO 13485:2016, Clause 4.1.4. Specifically, your firm's Change Control Procedure (SOP 2.4, Section 5.0, Rev. 1.30, Eff. Date August 28, 2020) requires that \"changes to production processes are documented on the change control form.\" Your firm failed to document the change from contract manufacturer (b)(4) to (b)(4) manufacturing via (b)(4) molding, which occurred on January 8, 2021. Furthermore, your firm did not evaluate the impact of this manufacturing change on the devices produced and the process controls necessary to address potential risks to product quality and end users. During the inspection you stated that \"an impact assessment was not conducted to evaluate effects on the quality management system and device quality.\"\nWe are unable to determine the adequacy of your corrective actions as your firm has not provided a response to the observations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Melissa Michurski, Establishment Assessment Team 2, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case #739966” when replying. If you have any questions about the contents of this letter, please contact: Rafael Padilla, Compliance Officer at Rafael.Padilla@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Pro-Optics, LLC","pro-optics-llc-734689-10052026","2026-11-03T01:02:17.615107+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpro-optics-llc-734689-10052026","2026-11-17T01:02:03.701861+00:00","Warning Letter","Issued","2026-10-27","734689","Medical Devices","Eric A. Nyman","2026-11-03T01:02:59.364+00:00","VIA Electronic Mail","2026-10-05",{"id":32,"raw":33,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":19,"letter_url":46,"updated_at":47,"action_type":22,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":52,"issuing_office":53,"recipient_name":54,"body_fetched_at":55,"delivery_method":56,"recipient_title":19,"reference_number":19,"action_taken_date":57,"medical_device_id":19,"response_letter_date":19},1500,[34,35,36,37,38,13,39,13],"\u003Ctime datetime=\"2024-04-30T13:20:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-01T05:00:00Z\">02\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhi-pro-feeds-llc-667790-02012024\">Hi-Pro Feeds, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations West III","CGMP\u002FMedicated Feeds\u002FAdulterated\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhi-pro-feeds-llc-667790-08212024\">\u003Ctime datetime=\"2024-08-30T04:00:00Z\">08\u002F30\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","CGMP\u002FMedicated Feeds\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Overnight\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Clifton Morgan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager \u002F President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hi-Pro Feeds, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1201 E. 11th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Friona\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>79035-1410\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 01, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CMS# 667790\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Morgan:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your FDA licensed medicated feed manufacturing facility, located at 1201 E 11th St. Friona, TX 79035-1410 from July 31 through August 4, 2023. This inspection was initiated in response to a Reportable Food Registry (RFR) report your employee filed after receiving a consumer complaint involving multiple illnesses and deaths in your customer’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> goat herd after consuming a medicated goat feed, Windy Acres Show Ration (lot number 0015932234), that was manufactured by your facility on April 19, 2023. Your third-party lab analyzed samples of goat feed from the customer as well as your retained samples and reported the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from urea, an animal feed ingredient for which the goat food was not formulated to include. Elevated urea levels can cause serious health consequences and death in ruminant animals such as cattle, sheep, goats, and deer. The sample results, the farm’s veterinarian’s statement, and necropsy reports from a goat that consumed this feed indicate the goats died from \u003Cstrong>(b)(4)\u003C\u002Fstrong> toxicity. Your facility conducted a recall of this goat feed on July 7, 2023.\u003C\u002Fp>\n\n\u003Cp>During the inspection, FDA Investigator found evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507) which causes your products to be adulterated.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The doing of any act to a food after shipment of the food and\u002For its components in interstate commerce and while the food is held for sale (whether or not the first sale) that results in the food being adulterated or misbranded is prohibited.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls requirements of 21 CFR Part 507 (located in subparts A, C, D, E, and F of Part 507) is a prohibited act.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, you failed to report a reportable food to the Reportable Food Registry (RFR) within twenty-four hours of determining that an animal food is a reportable food (i.e., an animal food for which there is a reasonable probability that the use of, or exposure to, such animal food will cause serious adverse health consequences or death to animals).\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Failure to submit a required reportable food report is a prohibited act.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>You may find the FD&amp;C Act and FDA’s regulations through links on the FDA’s website at https:\u002F\u002Fwww.fda.gov\u002F.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of our inspection, you were issued a Form FDA 483, Inspectional Observations (FDA-483). We received your written email responses to these observations dated August 24 and September 5, 2023 and address your corrective actions below in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls Requirements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility, the FDA Investigator obtained evidence of significant violations of these requirements, which included but were not limited to the following:\u003C\u002Fp>\n\n\u003Cp>You did not conduct a hazard analysis to identify and evaluate, based on experience, illness data, scientific reports, and other information, known or reasonably foreseeable hazards for each type of animal food you manufacture, process, pack, or hold at your facility to determine whether there are any hazards requiring a preventive control, as required by 21 CFR 507.33(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your written hazard analysis failed to identify the known or reasonably foreseeable chemical hazard of nutrient toxicity associated with excess urea in the animal food you produce. Your facility uses urea as an ingredient in some of your products, which could be toxic at excess levels to goats and other species. On April 19, 2023, you manufactured \u003Cstrong>(b)(4)\u003C\u002Fstrong> of a custom medicated goat feed, Windy Acres Show Ration (lot number 0015932234), that was not formulated to contain urea but was subsequently found to contain elevated levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from urea. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, \u003Cstrong>(b)(4)\u003C\u002Fstrong> 50-pound bags were sold to a customer who fed the goat feed to their \u003Cstrong>(b)(4)\u003C\u002Fstrong> goats on May 7, 2023. The customer reported on May 7, 2023, that one goat was “bellowing in pain, foaming at mouth, labored breathing, restless, muscle and tail twitching, up and down, laid down, and died within two hrs of ingesting feed.” The customer subsequently reported additional goat deaths. You performed a root cause investigation and reasoned that the elevated levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was due to loose bulk urea forming a plug in the distributor head and this plug, containing an unknown amount of urea, was dislodged into a bin of soybean meal that was subsequently used in the production of the Windy Acres Show Ration product.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Evaluation of your responses:\u003C\u002Fu>\u003Cbr>\nYour written responses to the FDA-483 included an updated Animal Food Safety Plan and hazard analysis dated August 21, 2023. In your updated hazard analysis, you address \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but only at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step. Your hazard analysis does not fully address the known or reasonably foreseeable hazard of nutrient toxicity related to the use of urea in your animal food. For example, your hazard analysis does not address the other areas in which urea carryover could happen, such as at the distributor head or related conveyance steps. Further, your response does not indicate that you evaluated the likelihood of urea carryover at each step of your process where the hazards associated with urea could be introduced or enhanced, such as at the receiving step. We are unable to fully evaluate your corrective actions because you did not provide supporting documentation to demonstrate you have adequately evaluated nutrient toxicities and deficiencies at each production step where nutrient toxicities and deficiencies may be associated.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Reportable Food Registry (RFR)\u003C\u002Fstrong>\u003C\u002Fu>\u003Cbr>\nYou failed to report a reportable food to the RFR within twenty-four (24) hours of determining that an article of food is a reportable food, as required by section 417(d)(1) of the FD&amp;C Act. Specifically, on May 7, 2023, your customer informed you that they observed multiple illnesses and deaths of \u003Cstrong>(b)(4)\u003C\u002Fstrong> goats that consumed Windy Acres Show Ration (lot number 0015932234), a medicated custom goat feed you manufactured. Your company responded by sending a sales representative to the customer’s farm to collect samples from opened bags of goat feed on May 8, 2023. Results from those samples were reported on May 17, 2023 and documented elevated levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from urea, an ingredient the feed was not formulated to include. Subsequent sampling of retained samples and additional finished product were submitted for analysis and further demonstrated the presence of urea.; However, you did not file a RFR report until July 13, 2023.\u003C\u002Fp>\n\n\u003Cp>The Reportable Food Registry was established to provide a reliable mechanism to track patterns of adulteration in food (including animal food) to support efforts by FDA to target limited inspection resources to protect the public health. It requires a “responsible party” to file reportable food reports. The responsible party is the person who submits the registration under section 415 of the FD&amp;C Act for a food facility that is required to register, at which the reportable food was manufactured, processed, packed, or held.\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The responsible party is required to file a notification within 24 hours of determining that an article of food is a reportable food.\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Failure to submit a required reportable food report is a prohibited act under the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Guidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\u003C\u002Fli>\n\t\u003Cli>Guidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\u003C\u002Fli>\n\t\u003Cli>Draft Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that you have complied with the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to Chad J. Whitwell, Compliance Officer, at chad.whitwell@fda.hhs.gov (preferred) or at U.S. Food and Drug Administration, 1201 Main St, Suite 7200, Dallas, TX 75202. If you have questions regarding any issues in this letter, please contact Mr. Whitwell at 214-253-5328.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Edmundo Garcia, Jr.\u003Cbr>\nProgram Division Director HAF West 3\u003Cbr>\nDallas District Director\u003C\u002Fp>\n\n\u003Cp>cc: Mr. Mark W. Osborn, Plant Manager\u003Cbr>\nHi-Pro Feeds, LLC\u003Cbr>\n1201 E 11th St\u003Cbr>\nFriona, TX 79035-1410\u003C\u002Fp>\n\n\u003Cp>cc: Mary Sasser, Program Director\u003Cbr>\nOffice of the Texas State Chemist\u003Cbr>\nATTN: Mary Sasser, Program Director\u003Cbr>\nP.O. Box 3160\u003Cbr>\nCollege Station, TX 77841-3160\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(k) of the FD&amp;C Act [21 U.S.C. § 331(k)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(uu) of the FD&amp;C Act [21 U.S.C. § 331(uu)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See Section 417(d)(1) of the FD&amp;C Act [21 U.S.C. § 350f(d)(1)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(mm) of the FD&amp;C Act [21 U.S.C. § 331(mm)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See Section 417(a)(1) of the FD&amp;C Act [21 U.S.C. § 350f(a)(1)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> See Section 417(d)(1) of the FD&amp;C Act [21 U.S.C. § 350f(d)(1)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(mm) of the FD&amp;C Act [21 U.S.C. § 331(mm)].\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Overnight\n\nProduct:\n\nAnimal & Veterinary\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Clifton Morgan\n\nRecipient Title\n\nGeneral Manager \u002F President\n\nHi-Pro Feeds, LLC\n\n1201 E. 11th Street\n\nFriona, TX 79035-1410\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West III\n\nUnited States\n\nFebruary 01, 2024\n\nWARNING LETTER\n\nCMS# 667790\n\nDear Mr. Morgan:\n\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your FDA licensed medicated feed manufacturing facility, located at 1201 E 11th St. Friona, TX 79035-1410 from July 31 through August 4, 2023. This inspection was initiated in response to a Reportable Food Registry (RFR) report your employee filed after receiving a consumer complaint involving multiple illnesses and deaths in your customer’s (b)(4) goat herd after consuming a medicated goat feed, Windy Acres Show Ration (lot number 0015932234), that was manufactured by your facility on April 19, 2023. Your third-party lab analyzed samples of goat feed from the customer as well as your retained samples and reported the presence of (b)(4) from urea, an animal feed ingredient for which the goat food was not formulated to include. Elevated urea levels can cause serious health consequences and death in ruminant animals such as cattle, sheep, goats, and deer. The sample results, the farm’s veterinarian’s statement, and necropsy reports from a goat that consumed this feed indicate the goats died from (b)(4) toxicity. Your facility conducted a recall of this goat feed on July 7, 2023.\n\nDuring the inspection, FDA Investigator found evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507) which causes your products to be adulterated.1 The doing of any act to a food after shipment of the food and\u002For its components in interstate commerce and while the food is held for sale (whether or not the first sale) that results in the food being adulterated or misbranded is prohibited.2 Failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls requirements of 21 CFR Part 507 (located in subparts A, C, D, E, and F of Part 507) is a prohibited act.3\n\nAdditionally, you failed to report a reportable food to the Reportable Food Registry (RFR) within twenty-four hours of determining that an animal food is a reportable food (i.e., an animal food for which there is a reasonable probability that the use of, or exposure to, such animal food will cause serious adverse health consequences or death to animals).4 Failure to submit a required reportable food report is a prohibited act.5\n\nYou may find the FD&C Act and FDA’s regulations through links on the FDA’s website at https:\u002F\u002Fwww.fda.gov\u002F.\n\nAt the conclusion of our inspection, you were issued a Form FDA 483, Inspectional Observations (FDA-483). We received your written email responses to these observations dated August 24 and September 5, 2023 and address your corrective actions below in relation to each of the noted violations.\n\nHazard Analysis and Risk-Based Preventive Controls Requirements\n\nYour animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility, the FDA Investigator obtained evidence of significant violations of these requirements, which included but were not limited to the following:\n\nYou did not conduct a hazard analysis to identify and evaluate, based on experience, illness data, scientific reports, and other information, known or reasonably foreseeable hazards for each type of animal food you manufacture, process, pack, or hold at your facility to determine whether there are any hazards requiring a preventive control, as required by 21 CFR 507.33(a).\n\nSpecifically, your written hazard analysis failed to identify the known or reasonably foreseeable chemical hazard of nutrient toxicity associated with excess urea in the animal food you produce. Your facility uses urea as an ingredient in some of your products, which could be toxic at excess levels to goats and other species. On April 19, 2023, you manufactured (b)(4) of a custom medicated goat feed, Windy Acres Show Ration (lot number 0015932234), that was not formulated to contain urea but was subsequently found to contain elevated levels of (b)(4) from urea. On (b)(4), (b)(4) 50-pound bags were sold to a customer who fed the goat feed to their (b)(4) goats on May 7, 2023. The customer reported on May 7, 2023, that one goat was “bellowing in pain, foaming at mouth, labored breathing, restless, muscle and tail twitching, up and down, laid down, and died within two hrs of ingesting feed.” The customer subsequently reported additional goat deaths. You performed a root cause investigation and reasoned that the elevated levels of (b)(4) was due to loose bulk urea forming a plug in the distributor head and this plug, containing an unknown amount of urea, was dislodged into a bin of soybean meal that was subsequently used in the production of the Windy Acres Show Ration product.\n\nEvaluation of your responses:\n\nYour written responses to the FDA-483 included an updated Animal Food Safety Plan and hazard analysis dated August 21, 2023. In your updated hazard analysis, you address (b)(4), but only at the “(b)(4)” step. Your hazard analysis does not fully address the known or reasonably foreseeable hazard of nutrient toxicity related to the use of urea in your animal food. For example, your hazard analysis does not address the other areas in which urea carryover could happen, such as at the distributor head or related conveyance steps. Further, your response does not indicate that you evaluated the likelihood of urea carryover at each step of your process where the hazards associated with urea could be introduced or enhanced, such as at the receiving step. We are unable to fully evaluate your corrective actions because you did not provide supporting documentation to demonstrate you have adequately evaluated nutrient toxicities and deficiencies at each production step where nutrient toxicities and deficiencies may be associated.\n\nReportable Food Registry (RFR)\n\nYou failed to report a reportable food to the RFR within twenty-four (24) hours of determining that an article of food is a reportable food, as required by section 417(d)(1) of the FD&C Act. Specifically, on May 7, 2023, your customer informed you that they observed multiple illnesses and deaths of (b)(4) goats that consumed Windy Acres Show Ration (lot number 0015932234), a medicated custom goat feed you manufactured. Your company responded by sending a sales representative to the customer’s farm to collect samples from opened bags of goat feed on May 8, 2023. Results from those samples were reported on May 17, 2023 and documented elevated levels of (b)(4) from urea, an ingredient the feed was not formulated to include. Subsequent sampling of retained samples and additional finished product were submitted for analysis and further demonstrated the presence of urea.; However, you did not file a RFR report until July 13, 2023.\n\nThe Reportable Food Registry was established to provide a reliable mechanism to track patterns of adulteration in food (including animal food) to support efforts by FDA to target limited inspection resources to protect the public health. It requires a “responsible party” to file reportable food reports. The responsible party is the person who submits the registration under section 415 of the FD&C Act for a food facility that is required to register, at which the reportable food was manufactured, processed, packed, or held.6 The responsible party is required to file a notification within 24 hours of determining that an article of food is a reportable food.7 Failure to submit a required reportable food report is a prohibited act under the FD&C Act.8\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure and injunction.\n\nFor more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\n\nGuidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\n\nGuidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\n\nDraft Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that you have complied with the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to Chad J. Whitwell, Compliance Officer, at chad.whitwell@fda.hhs.gov (preferred) or at U.S. Food and Drug Administration, 1201 Main St, Suite 7200, Dallas, TX 75202. If you have questions regarding any issues in this letter, please contact Mr. Whitwell at 214-253-5328.\n\nSincerely,\n\n\u002FS\u002F\n\nEdmundo Garcia, Jr.\n\nProgram Division Director HAF West 3\n\nDallas District Director\n\ncc: Mr. Mark W. Osborn, Plant Manager\n\nHi-Pro Feeds, LLC\n\n1201 E 11th St\n\nFriona, TX 79035-1410\n\ncc: Mary Sasser, Program Director\n\nOffice of the Texas State Chemist\n\nATTN: Mary Sasser, Program Director\n\nP.O. Box 3160\n\nCollege Station, TX 77841-3160\n\n__________________________\n\n1 See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\n\n2 See Section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].\n\n3 See Section 301(uu) of the FD&C Act [21 U.S.C. § 331(uu)].\n\n4 See Section 417(d)(1) of the FD&C Act [21 U.S.C. § 350f(d)(1)].\n\n5 See Section 301(mm) of the FD&C Act [21 U.S.C. § 331(mm)].\n\n6 See Section 417(a)(1) of the FD&C Act [21 U.S.C. § 350f(a)(1)].\n\n7 See Section 417(d)(1) of the FD&C Act [21 U.S.C. § 350f(d)(1)].\n\n8 See Section 301(mm) of the FD&C Act [21 U.S.C. § 331(mm)].","Hi-Pro Feeds, LLC","hi-pro-feeds-llc-667790-02012024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhi-pro-feeds-llc-667790-02012024","2026-10-26T08:08:54.704188+00:00","Closed Out","2024-04-30","667790","Animal & VeterinaryFood & Beverages","2024-08-30","Division of Human and Animal Food Operations West III","Mr. Clifton Morgan","2026-08-20T00:09:17.249+00:00","UPS Overnight","2024-02-01",{"id":59,"raw":60,"subject":65,"body_html":66,"body_text":67,"firm_name":68,"letter_id":69,"created_at":70,"fei_number":19,"letter_url":71,"updated_at":72,"action_type":22,"case_status":23,"posted_date":73,"marcs_cms_no":74,"product_type":75,"closeout_date":19,"issuing_office":64,"recipient_name":76,"body_fetched_at":77,"delivery_method":78,"recipient_title":19,"reference_number":19,"action_taken_date":79,"medical_device_id":19,"response_letter_date":19},2351,[61,62,63,64,65,13,13,13],"\u003Ctime datetime=\"2022-11-15T14:20:00Z\">11\u002F15\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-26T04:00:00Z\">10\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flucero-produce-ii-corp-640910-10262022\">Lucero Produce II Corp.\u003C\u002Fa>","Division of Northeast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Olivia Lucero\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Lucero Produce II Corp.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1250 Randall Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bronx\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10474\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 26, 2022\u003C\u002Fp>\n\n\u003Cp>Re: CMS# 640910\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Olivia Lucero:\u003C\u002Fp>\n\n\u003Cp>On July 12 through July 22, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Lucero Produce II Corp. located at 1250 Randall Avenue, Bronx, NY 10474. We also conducted inspections on August 28, 2018, and from January 4 to 20, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the most recent inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your response on August 9, 2022, in which you stated that you needed more time to provide the appropriate documentation. As of the date of this letter, we have not received any additional response or documents. We are unable to evaluate the adequacy of your response because you did not provide any additional details or documentation demonstrating you have implemented any corrective action to comply with the FSVP regulation.\u003C\u002Fp>\n\n\u003Cp>Your significant violation of the FSVP regulation is as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any of the foods you import, including each of the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Papalos, Epazote and Pipachas imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You import fresh produce, that is “covered produce” as defined in 21 CFR 112.3. As an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&amp;C Act (21 U.S.C. § 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart, L.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Feryal Ahmad, Compliance Officer, Division of Northeast Imports, ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Feryal.Ahmad@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ahmad via email at Feryal.Ahmad@fda.hhs.gov. Please reference CMS# 640910 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Anna Alexander\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Olivia Lucero\n\nLucero Produce II Corp.\n\n1250 Randall Avenue\n\nBronx, NY 10474\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\nOctober 26, 2022\n\nRe: CMS# 640910\n\nDear Ms. Olivia Lucero:\n\nOn July 12 through July 22, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Lucero Produce II Corp. located at 1250 Randall Avenue, Bronx, NY 10474. We also conducted inspections on August 28, 2018, and from January 4 to 20, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the most recent inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your response on August 9, 2022, in which you stated that you needed more time to provide the appropriate documentation. As of the date of this letter, we have not received any additional response or documents. We are unable to evaluate the adequacy of your response because you did not provide any additional details or documentation demonstrating you have implemented any corrective action to comply with the FSVP regulation.\n\nYour significant violation of the FSVP regulation is as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any of the foods you import, including each of the following:\n\nPapalos, Epazote and Pipachas imported from (b)(4) located in (b)(4)\n\nYou import fresh produce, that is “covered produce” as defined in 21 CFR 112.3. As an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&C Act (21 U.S.C. § 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart, L.\n\n(b)(3)(A)\n\nAs a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\n\n(b)(3)(A)\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Feryal Ahmad, Compliance Officer, Division of Northeast Imports, ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Feryal.Ahmad@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ahmad via email at Feryal.Ahmad@fda.hhs.gov. Please reference CMS# 640910 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnna Alexander\n\nActing Program Division Director\n\nDivision of Northeast Imports","Lucero Produce II Corp.","lucero-produce-ii-corp-640910-10262022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flucero-produce-ii-corp-640910-10262022","2026-10-26T08:09:16.700964+00:00","2022-11-15","640910","Food & Beverages","Ms. Olivia Lucero","2026-08-20T01:26:53.192+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2022-10-26",{"id":81,"raw":82,"subject":88,"body_html":89,"body_text":90,"firm_name":91,"letter_id":92,"created_at":93,"fei_number":19,"letter_url":94,"updated_at":95,"action_type":22,"case_status":23,"posted_date":96,"marcs_cms_no":97,"product_type":98,"closeout_date":19,"issuing_office":86,"recipient_name":99,"body_fetched_at":100,"delivery_method":101,"recipient_title":19,"reference_number":102,"action_taken_date":103,"medical_device_id":19,"response_letter_date":19},221,[83,84,85,86,87,13,13,13],"\u003Ctime datetime=\"2026-04-21T04:00:00Z\">04\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-14T04:00:00Z\">04\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpro-numb-tattoo-numbing-spray-llc-722589-04142026\">Pro Numb Tattoo Numbing Spray, LLC \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC\u003Cbr \u002F>\r\n","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-63\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Justin T. Zahnter\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Pro Numb Tattoo Numbing Spray, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3778 Dixie Highway NE, Suite C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Palm Bay\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32905-2727\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-63\u003C\u002Fp>\u003Cp>April 14, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Zahnter:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pro Numb Tattoo Numbing Spray, LLC, FEI 3027228716, at 3778 Dixie Highway NE, Suite C, Palm Bay, from November 5 to 6, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Additionally, these drug products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your November 13, 2025 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately test batches of your drug products before release and distribution. You stated your firm does not perform finished product testing.\u003C\u002Fp>\u003Cp>In your response, you state you contracted a third-party laboratory to perform full release testing, and you implemented finished product specifications, Certificates of Analysis (COAs), and a standard operating procedure (SOP) for identity, strength, purity, and microbial testing.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sufficient details about the test methods and specifications you implemented for your over-the-counter (OTC) drug products to ensure each batch of your finished products met appropriate standards before release and distribution. Also, you do not commit to performing retrospective testing of your drug product retains (reserve samples) for batches already distributed in the U.S. market.\u003C\u002Fp>\u003Cp>Drug product batches must be tested for identity, strength, quality, and purity before release. Without sufficient release testing, defective drug products that may pose a risk to consumers are unlikely to be detected.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>Procedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC topical analgesic drug products without adequate assurance of the quality of raw materials. For example, you did not test incoming components, such as your active pharmaceutical ingredients, for identity before using them in the manufacture of your drug products. Additionally, you relied on your suppliers’ COAs without establishing the reliability of each of your suppliers’ analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that your raw materials, including but not limited to active pharmaceutical ingredients, conform to the appropriate specifications before their use in the manufacture of your drug products. As a manufacturer, you are responsible for sampling, testing, and examining drug components before their use in production to ensure adequate quality.\u003C\u002Fp>\u003Cp>Your firm also used \u003Cstrong>(b)(4)\u003C\u002Fstrong> from an external source as a component in your finished drug products without conducting adequate testing to ensure it consistently meets the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, United States Pharmacopeia (USP) monograph specifications and appropriate microbial limits.\u003C\u002Fp>\u003Cp>Because \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used as a component in your nonsterile drug products, the lack of data regarding the quality of your incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong> poses a potential risk of introducing objectionable microbial contamination into your products. \u003Cstrong>(b)(4)\u003C\u002Fstrong> purposes must be suitable for its intended use and tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\u003Cp>In your response, you state you created SOPs for raw material receipt, quarantine, sampling, testing, handling, and approval. You also state you implemented raw material testing at a third-party laboratory and implemented testing for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide raw material specifications, test results, and copies of your SOPs for testing raw materials, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also fail to provide sufficient details demonstrating how you qualified the contract laboratory used for testing raw materials. In addition, your response does not state if you plan to perform retrospective testing for all lots of components already used to manufacture your drug products, and if you plan to establish the reliability of each of your suppliers’ analyses.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality;\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data);\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>A procedure for your water testing, including sampling, that also specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to demonstrate the quality attributes of your drug products remain acceptable throughout the labeled expiration period. For example, during the inspection, you indicated to the investigator you recorded microbial results on the stability-study data sheet without performing the testing and without any supporting data. You also did not record assay results on your stability-study data sheets for multiple stability time points.\u003C\u002Fp>\u003Cp>In your response, you explain you have established a compliant stability program, which includes establishing stability SOPs and protocols, implementing accelerated and long-term stability conditions, and submitting initial stability samples to an accredited laboratory. You also state you removed the unsupported \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date while you determine whether the shelf-life is supported by data.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Also, you do not specify the expiration date that you are currently using for your finished products after you removed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o all procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003Cli>The current expiry date for your finished drug products.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to validate your manufacturing processes for your OTC drug products (for example, Pro Numb Tattoo Numbing Spray 5% Lidocaine and Pro Numb Tattoo Numbing Spray 4% Lidocaine for sensitive skin). When asked to provide validation studies for your manufacturing process, you acknowledged not being familiar with process validation requirements.\u003C\u002Fp>\u003Cp>In addition, the process design and controls for your production did not demonstrate reproducibility or consistency in your manufacturing process. For example, for a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to achieve your target batch size, and then you \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Also, you explained your filling process is to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, without established fill volume controls.\u003C\u002Fp>\u003Cp>Furthermore, you explained you perform viscosity in-process testing of your bulk drug product by looking at it, with a specification of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and without using a viscometer or any other appropriate laboratory instrumentation for your viscosity determination.\u003C\u002Fp>\u003Cp>You did not establish scientifically sound and technically precise process parameters and process controls to ensure quality, homogeneity, and content uniformity, including fill volume of your drug products.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not commit to providing a detailed plan to validate your manufacturing processes.\u003C\u002Fp>\u003Cp>You are responsible for designing and controlling your manufacturing processes to ensure that they reproducibly yield drug products meeting predefined process parameters and quality attributes.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>A timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of adequate batch production and control records, with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\u003C\u002Fli>\u003Cli>Adequate training for employees engaged in the manufacture, processing, packing, or holding of drug products (21 CFR 211.25(a)).\u003C\u002Fli>\u003Cli>Establishment of routine calibration and written records of calibration checks according to a written program designed to ensure proper performance of equipment used in the manufacture, processing, packing, and holding of a drug product (21 CFR 211.68(a)).\u003C\u002Fli>\u003Cli>Adequate storage and warehousing of drug products, including but not limited to appropriate monitoring of storage conditions for temperature and humidity (21 CFR 211.142).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state you have established an independent QU; revised and approved all SOPs; remediated your batch manufacturing records; created training files, including complete GMP training of all personnel; implemented an equipment calibration program; and installed calibrated temperature and humidity data loggers with defined storage ranges to monitor your storage areas.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sufficient information and supporting documentation to verify the adequacy and effectiveness of your corrective actions.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>ICH Q10 Pharmaceutical Quality System, as well as Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload and https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload, respectively.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A complete, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>Your QU authority and responsibilities procedure, SOP-QA-001.\u003C\u002Fli>\u003Cli>Your organizational chart and current number of CGMP employees.\u003C\u002Fli>\u003Cli>Your procedure for your environmental controls and alarm limits for your storage areas.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products’ labeling, including your website, https:\u002F\u002Ftattoonumbingsprays.com\u002F, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cu>PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN\u003C\u002Fu>”\u003Cbr>“Topical Anesthetic to take away pain” [from your product labels]\u003C\u002Fp>\u003Cp>“Takes away Pain, Swelling, and Redness during tattoo procedures” [from your product labels]\u003C\u002Fp>\u003Cp>“Temporarily takes away pain, itching, and swelling associated with anorectal disorders or pain-sensitive procedures” [from your product labels]\u003C\u002Fp>\u003Cp>“Instantly removes pain…” [from your product website]\u003C\u002Fp>\u003Cp>“Tattoo Pain Relief” [from your product website]\u003C\u002Fp>\u003Cp>\u003Cu>“PRO NUMB TATTOO NUMBING SPRAY”\u003C\u002Fu>\u003Cbr>“5% lidocaine temporarily blocks pain signals in the brain” [from your product website]\u003C\u002Fp>\u003Cp>\u003Cu>“PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN”\u003C\u002Fu>\u003Cbr>“4% lidocaine temporarily blocks pain signals in the brain” [from your product website]\u003C\u002Fp>\u003Cp>\u003Cu>“TKTX Deep Numbs”\u003C\u002Fu>\u003Cbr>“Usable Range Micro Needle Pain Tattooing Body Piercing, Laser Tattoo Removal, Laser Hair Removal, Waxing, Permanent Cosmetics” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are intended for use as external analgesic drug products, among other intended uses.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (“M017”).\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” do not conform to the conditions specified in M017 for the reasons described below.\u003C\u002Fp>\u003Cp>The labeled concentrations and\u002For combinations of active ingredients identified in the product labeling for “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” do not conform to the conditions of use set forth in M017. Specifically, lidocaine, an active ingredient labeled to be in all three products, is listed as lidocaine 5% in “TKTX Deep Numbs” and lidocaine hydrochloride 5% in “PRO NUMB TATTOO NUMBING SPRAY.” This concentration is above the 0.5% to 4% concentration range of lidocaine and lidocaine hydrochloride permitted under M017.10(a).\u003C\u002Fp>\u003Cp>As formulated, both “PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN” contain a combination of the active ingredients lidocaine and epinephrine, and “TKTX Deep Numbs” contains a combination of the active ingredients lidocaine, epinephrine, and prilocaine. None of these combinations of active ingredients in a single external analgesic drug product are permitted under M017.20. Furthermore, epinephrine, epinephrine HCl, and prilocaine are not permitted ingredients under M017, and prilocaine is not a permitted active ingredient in any final administrative order issued in accordance with section 505G.\u003C\u002Fp>\u003Cp>Additionally, the labeling for “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” includes indications that are not permitted for external analgesic drug products under M017.50(b). Indications related to tattooing, piercing, and\u002For minor cosmetic procedures are not permitted under M017 or in any other final administrative order in accordance with section 505G.\u003C\u002Fp>\u003Cp>Thus, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drugs into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of any applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355. The introduction or delivery for introduction of misbranded drugs into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On January 28, 2026, FDA held a teleconference with you recommending you consider removing any batches of Pro Numb Tattoo Numbing Spray and Pro Numb Tattoo Numbing Spray for Sensitive Skin currently in distribution from the U.S. market.\u003C\u002Fp>\u003Cp>You communicated your commitment to voluntary recall all batches of your Pro Numb Tattoo Numbing Spray drug products within expiry.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3027228716 and ATTN: Sai Dharmaraj.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that “PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN” also appear to be indicated to relieve pain associated with anorectal disorders. OTC anorectal drug products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M015: Anorectal Drug Products for Over-the-Counter Human Use (“M015”). (See Order ID OTC000009, available at FDA’s website OTC Monographs@FDA). These products also do not conform to the conditions set forth in this monograph.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfm.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-63\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Justin T. Zahnter\n\nRecipient Title\n\nOwner\n\nPro Numb Tattoo Numbing Spray, LLC\n\n3778 Dixie Highway NE, Suite C\n\nPalm Bay, FL 32905-2727\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-63\nApril 14, 2026\nDear Mr. Zahnter:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pro Numb Tattoo Numbing Spray, LLC, FEI 3027228716, at 3778 Dixie Highway NE, Suite C, Palm Bay, from November 5 to 6, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nAdditionally, these drug products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nCGMP Violations\nWe reviewed your November 13, 2025 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm failed to adequately test batches of your drug products before release and distribution. You stated your firm does not perform finished product testing.\nIn your response, you state you contracted a third-party laboratory to perform full release testing, and you implemented finished product specifications, Certificates of Analysis (COAs), and a standard operating procedure (SOP) for identity, strength, purity, and microbial testing.\nYour response is inadequate. You do not provide sufficient details about the test methods and specifications you implemented for your over-the-counter (OTC) drug products to ensure each batch of your finished products met appropriate standards before release and distribution. Also, you do not commit to performing retrospective testing of your drug product retains (reserve samples) for batches already distributed in the U.S. market.\nDrug product batches must be tested for identity, strength, quality, and purity before release. Without sufficient release testing, defective drug products that may pose a risk to consumers are unlikely to be detected.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nProcedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures OTC topical analgesic drug products without adequate assurance of the quality of raw materials. For example, you did not test incoming components, such as your active pharmaceutical ingredients, for identity before using them in the manufacture of your drug products. Additionally, you relied on your suppliers’ COAs without establishing the reliability of each of your suppliers’ analyses at appropriate intervals.\nWithout adequate testing, you do not have scientific evidence that your raw materials, including but not limited to active pharmaceutical ingredients, conform to the appropriate specifications before their use in the manufacture of your drug products. As a manufacturer, you are responsible for sampling, testing, and examining drug components before their use in production to ensure adequate quality.\nYour firm also used (b)(4) from an external source as a component in your finished drug products without conducting adequate testing to ensure it consistently meets the (b)(4), United States Pharmacopeia (USP) monograph specifications and appropriate microbial limits.\nBecause (b)(4) is used as a component in your nonsterile drug products, the lack of data regarding the quality of your incoming (b)(4) poses a potential risk of introducing objectionable microbial contamination into your products. (b)(4) purposes must be suitable for its intended use and tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\nIn your response, you state you created SOPs for raw material receipt, quarantine, sampling, testing, handling, and approval. You also state you implemented raw material testing at a third-party laboratory and implemented testing for your (b)(4), including testing for (b)(4).\nYour response is inadequate. You do not provide raw material specifications, test results, and copies of your SOPs for testing raw materials, including (b)(4). You also fail to provide sufficient details demonstrating how you qualified the contract laboratory used for testing raw materials. In addition, your response does not state if you plan to perform retrospective testing for all lots of components already used to manufacture your drug products, and if you plan to establish the reliability of each of your suppliers’ analyses.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\no an assessment of all materials to determine whether they are consistently of acceptable quality;\no a review to ensure assigned expiration or retest dates are appropriate (supported by data);\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nA procedure for your water testing, including sampling, that also specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nYou failed to demonstrate the quality attributes of your drug products remain acceptable throughout the labeled expiration period. For example, during the inspection, you indicated to the investigator you recorded microbial results on the stability-study data sheet without performing the testing and without any supporting data. You also did not record assay results on your stability-study data sheets for multiple stability time points.\nIn your response, you explain you have established a compliant stability program, which includes establishing stability SOPs and protocols, implementing accelerated and long-term stability conditions, and submitting initial stability samples to an accredited laboratory. You also state you removed the unsupported (b)(4) expiration date while you determine whether the shelf-life is supported by data.\nYour response is inadequate. You do not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Also, you do not specify the expiration date that you are currently using for your finished products after you removed the (b)(4) expiration date.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive, independent investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no detailed definition of the specific attributes to be tested at each station (timepoint)\no all procedures that describe these and other elements of your remediated stability program.\nThe current expiry date for your finished drug products.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\n4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to validate your manufacturing processes for your OTC drug products (for example, Pro Numb Tattoo Numbing Spray 5% Lidocaine and Pro Numb Tattoo Numbing Spray 4% Lidocaine for sensitive skin). When asked to provide validation studies for your manufacturing process, you acknowledged not being familiar with process validation requirements.\nIn addition, the process design and controls for your production did not demonstrate reproducibility or consistency in your manufacturing process. For example, for a (b)(4) to achieve your target batch size, and then you (b)(4). Also, you explained your filling process is to (b)(4), without established fill volume controls.\nFurthermore, you explained you perform viscosity in-process testing of your bulk drug product by looking at it, with a specification of “(b)(4),” and without using a viscometer or any other appropriate laboratory instrumentation for your viscosity determination.\nYou did not establish scientifically sound and technically precise process parameters and process controls to ensure quality, homogeneity, and content uniformity, including fill volume of your drug products.\nYour response is inadequate. You do not commit to providing a detailed plan to validate your manufacturing processes.\nYou are responsible for designing and controlling your manufacturing processes to ensure that they reproducibly yield drug products meeting predefined process parameters and quality attributes.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nA timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\nA comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\n5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\nEstablishment of adequate batch production and control records, with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\nAdequate training for employees engaged in the manufacture, processing, packing, or holding of drug products (21 CFR 211.25(a)).\nEstablishment of routine calibration and written records of calibration checks according to a written program designed to ensure proper performance of equipment used in the manufacture, processing, packing, and holding of a drug product (21 CFR 211.68(a)).\nAdequate storage and warehousing of drug products, including but not limited to appropriate monitoring of storage conditions for temperature and humidity (21 CFR 211.142).\nIn your response, you state you have established an independent QU; revised and approved all SOPs; remediated your batch manufacturing records; created training files, including complete GMP training of all personnel; implemented an equipment calibration program; and installed calibrated temperature and humidity data loggers with defined storage ranges to monitor your storage areas.\nYour response is inadequate. You do not provide sufficient information and supporting documentation to verify the adequacy and effectiveness of your corrective actions.\nYour firm’s quality systems are inadequate. See FDA’s guidance document ICH Q10 Pharmaceutical Quality System, as well as Quality Systems Approach to Pharmaceutical CGMP Regulations, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload and https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload, respectively.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA complete, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nYour QU authority and responsibilities procedure, SOP-QA-001.\nYour organizational chart and current number of CGMP employees.\nYour procedure for your environmental controls and alarm limits for your storage areas.\nUnapproved New Drug and Misbranded Drug Violations\n“PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products’ labeling, including your website, https:\u002F\u002Ftattoonumbingsprays.com\u002F, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN”\n“Topical Anesthetic to take away pain” [from your product labels]\n“Takes away Pain, Swelling, and Redness during tattoo procedures” [from your product labels]\n“Temporarily takes away pain, itching, and swelling associated with anorectal disorders or pain-sensitive procedures” [from your product labels]\n“Instantly removes pain…” [from your product website]\n“Tattoo Pain Relief” [from your product website]\n“PRO NUMB TATTOO NUMBING SPRAY”\n“5% lidocaine temporarily blocks pain signals in the brain” [from your product website]\n“PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN”\n“4% lidocaine temporarily blocks pain signals in the brain” [from your product website]\n“TKTX Deep Numbs”\n“Usable Range Micro Needle Pain Tattooing Body Piercing, Laser Tattoo Removal, Laser Hair Removal, Waxing, Permanent Cosmetics” [from the product label]\nUnapproved New Drug Violations\nBased on the above labeling evidence, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are intended for use as external analgesic drug products, among other intended uses.1 As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (“M017”).2 However, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” do not conform to the conditions specified in M017 for the reasons described below.\nThe labeled concentrations and\u002For combinations of active ingredients identified in the product labeling for “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” do not conform to the conditions of use set forth in M017. Specifically, lidocaine, an active ingredient labeled to be in all three products, is listed as lidocaine 5% in “TKTX Deep Numbs” and lidocaine hydrochloride 5% in “PRO NUMB TATTOO NUMBING SPRAY.” This concentration is above the 0.5% to 4% concentration range of lidocaine and lidocaine hydrochloride permitted under M017.10(a).\nAs formulated, both “PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN” contain a combination of the active ingredients lidocaine and epinephrine, and “TKTX Deep Numbs” contains a combination of the active ingredients lidocaine, epinephrine, and prilocaine. None of these combinations of active ingredients in a single external analgesic drug product are permitted under M017.20. Furthermore, epinephrine, epinephrine HCl, and prilocaine are not permitted ingredients under M017, and prilocaine is not a permitted active ingredient in any final administrative order issued in accordance with section 505G.\nAdditionally, the labeling for “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” includes indications that are not permitted for external analgesic drug products under M017.50(b). Indications related to tattooing, piercing, and\u002For minor cosmetic procedures are not permitted under M017 or in any other final administrative order in accordance with section 505G.\nThus, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.3 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction of these unapproved new drugs into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of any applications approved under section 505 of the FD&C Act, 21 U.S.C. 355. The introduction or delivery for introduction of misbranded drugs into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nDrug Recall\nOn January 28, 2026, FDA held a teleconference with you recommending you consider removing any batches of Pro Numb Tattoo Numbing Spray and Pro Numb Tattoo Numbing Spray for Sensitive Skin currently in distribution from the U.S. market.\nYou communicated your commitment to voluntary recall all batches of your Pro Numb Tattoo Numbing Spray drug products within expiry.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit4 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3027228716 and ATTN: Sai Dharmaraj.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________\n1 We note that “PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN” also appear to be indicated to relieve pain associated with anorectal disorders. OTC anorectal drug products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M015: Anorectal Drug Products for Over-the-Counter Human Use (“M015”). (See Order ID OTC000009, available at FDA’s website OTC Monographs@FDA). These products also do not conform to the conditions set forth in this monograph.\n2 M017 reflects the conditions set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfm.\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\n4 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Pro Numb Tattoo Numbing Spray, LLC","pro-numb-tattoo-numbing-spray-llc-722589-04142026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpro-numb-tattoo-numbing-spray-llc-722589-04142026","2026-10-26T08:09:44.392139+00:00","2026-04-21","722589","Drugs","Mr. Justin T. Zahnter","2026-08-19T04:46:38.526+00:00","VIA EMAIL WITH READ RECEIPT","320-26-63","2026-04-14",{"id":105,"raw":106,"subject":65,"body_html":112,"body_text":113,"firm_name":114,"letter_id":115,"created_at":116,"fei_number":19,"letter_url":117,"updated_at":118,"action_type":22,"case_status":48,"posted_date":119,"marcs_cms_no":120,"product_type":75,"closeout_date":121,"issuing_office":110,"recipient_name":122,"body_fetched_at":123,"delivery_method":124,"recipient_title":19,"reference_number":19,"action_taken_date":125,"medical_device_id":19,"response_letter_date":19},3244,[107,108,109,110,65,13,111,13],"\u003Ctime datetime=\"2021-07-27T13:20:00Z\">07\u002F27\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-12T04:00:00Z\">07\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmario-hidalgo-dba-distribuidora-de-productos-alimenticios-el-paisita-614478-07122021\">Mario Hidalgo DBA Distribuidora de Productos Alimenticios El Paisita\u003C\u002Fa>","Division of Southwest Imports","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmario-hidalgo-dba-distribuidora-de-productos-alimenticios-el-paisita-614478-12092021\">\u003Ctime datetime=\"2022-02-01T05:00:00Z\">02\u002F01\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Mario Hidalgo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mario Hidalgo DBA Distribuidora de Productos Alimenticios El Paisita\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7404 N. 34th St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>McAllen\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78504\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mario_expomexicanfest@hotmail.com\"> mario_expomexicanfest@hotmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 12, 2021\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 614478\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mario Hidalgo,\u003C\u002Fp>\n\n\u003Cp>On March 9-10, 2021, the Food and Drug Administration conducted a remote Foreign Supplier Verification Program (FSVP) inspection of your firm Mario Hidalgo DBA Distribuidora de Productos Alimenticios El Paisita, located at 4712 N. 12th St., Apt. 47 McAllen, TX 78504-3604. We also conducted an inspection on November 29, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During our inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the food products you import, including Glorias w\u002FPecan Milk Candy and White Coconut Candy, both from Distribuidora De Productos Alimenticios El Paisita, Emiliano Carranza, located in Mexico and Tejocote \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not have FSVPs for these food products or for any products you import. Because of this significant violation, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the initial FSVP inspection on November 29, 2018 and the current inspection on March 9-10, 2021, our investigator provided you with Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response dated March 23, 2021 in which you stated that you planned to attend a Qualified Individual FSVP Training on March 29-30, 2021 and that you identify your firm as a very small importer based on a sales volume of less than 1 million dollars in the last three years. You also stated that you were requesting letters from your small foreign suppliers asking them “to explain what they do to ensure that the products they manufacture are safe for health or equivalent to US standards and will have them ready in my import records.” We contacted you on April 23, 2021 to follow up regarding whether you had attended the planned FSVP training on March 29-30 or had taken other steps to develop your FSVP, but we have not received a response to that communication. The FSVP implementation information you have provided thus far is not sufficient or specific enough to evaluate its adequacy at this time.\u003C\u002Fp>\n\n\u003Cp>Your significant violation of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR part 1.502(a). Specifically, your firm did not develop an FSVP for any of the foods you import, including each of the following:\u003C\u002Fp>\n\n\u003Cp>a. Glorias W\u002FPecan Milk Candy imported from Distribuidora De Productos Alimenticios El Paisita, located in Mexico.\u003Cbr>\nb. White Coconut Candy imported from Distribuidora De Productos Alimenticios El Paisita, located in Mexico.\u003Cbr>\nc. Tejocote \u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the foods you import, including Glorias W\u002FPecan Milk Candy and White Coconut Candy manufactured by Distribuidora De Productos Alimenticios El Paisita and Tejocote \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong> that appear to be in violation of section 805. We may place these foods you import from the identified foreign supplier on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at: \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: CDR Toby H. Hill, Compliance Officer, Division of Southwest Imports, One Main Place, 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any questions regarding this letter, you may contact Compliance Officer CDR Toby H. Hill via email at toby.hill@fda.hhs.gov. Please reference CMS # 614478 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nDivision of Southwest Imports Director\u003Cbr>\nOne Main Place\u003Cbr>\n1201 Main Street, Suite 7200\u003Cbr>\nDallas, TX 75202\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Mario Hidalgo\n\nRecipient Title\n\nOwner\n\nMario Hidalgo DBA Distribuidora de Productos Alimenticios El Paisita\n\n7404 N. 34th St.\n\nMcAllen, TX 78504\n\nUnited States\n\nmario_expomexicanfest@hotmail.com\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nWARNING LETTER\n\nJuly 12, 2021\n\nRe: CMS # 614478\n\nDear Mr. Mario Hidalgo,\n\nOn March 9-10, 2021, the Food and Drug Administration conducted a remote Foreign Supplier Verification Program (FSVP) inspection of your firm Mario Hidalgo DBA Distribuidora de Productos Alimenticios El Paisita, located at 4712 N. 12th St., Apt. 47 McAllen, TX 78504-3604. We also conducted an inspection on November 29, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring our inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the food products you import, including Glorias w\u002FPecan Milk Candy and White Coconut Candy, both from Distribuidora De Productos Alimenticios El Paisita, Emiliano Carranza, located in Mexico and Tejocote (b)(4) from (b)(4), located in (b)(4). You did not have FSVPs for these food products or for any products you import. Because of this significant violation, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the initial FSVP inspection on November 29, 2018 and the current inspection on March 9-10, 2021, our investigator provided you with Form FDA 483a, FSVP Observations.\n\nWe acknowledge receipt of your response dated March 23, 2021 in which you stated that you planned to attend a Qualified Individual FSVP Training on March 29-30, 2021 and that you identify your firm as a very small importer based on a sales volume of less than 1 million dollars in the last three years. You also stated that you were requesting letters from your small foreign suppliers asking them “to explain what they do to ensure that the products they manufacture are safe for health or equivalent to US standards and will have them ready in my import records.” We contacted you on April 23, 2021 to follow up regarding whether you had attended the planned FSVP training on March 29-30 or had taken other steps to develop your FSVP, but we have not received a response to that communication. The FSVP implementation information you have provided thus far is not sufficient or specific enough to evaluate its adequacy at this time.\n\nYour significant violation of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR part 1.502(a). Specifically, your firm did not develop an FSVP for any of the foods you import, including each of the following:\n\na. Glorias W\u002FPecan Milk Candy imported from Distribuidora De Productos Alimenticios El Paisita, located in Mexico.\n\nb. White Coconut Candy imported from Distribuidora De Productos Alimenticios El Paisita, located in Mexico.\n\nc. Tejocote (b)(4) imported from (b)(4), located in (b)(4).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the foods you import, including Glorias W\u002FPecan Milk Candy and White Coconut Candy manufactured by Distribuidora De Productos Alimenticios El Paisita and Tejocote (b)(4) manufactured by (b)(4) that appear to be in violation of section 805. We may place these foods you import from the identified foreign supplier on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to the Food and Drug Administration, Attention: CDR Toby H. Hill, Compliance Officer, Division of Southwest Imports, One Main Place, 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any questions regarding this letter, you may contact Compliance Officer CDR Toby H. Hill via email at toby.hill@fda.hhs.gov. Please reference CMS # 614478 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nDivision of Southwest Imports Director\n\nOne Main Place\n\n1201 Main Street, Suite 7200\n\nDallas, TX 75202","Mario Hidalgo DBA Distribuidora de Productos Alimenticios El Paisita","mario-hidalgo-dba-distribuidora-de-productos-alimenticios-el-paisita-614478-07122021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmario-hidalgo-dba-distribuidora-de-productos-alimenticios-el-paisita-614478-07122021","2026-10-26T08:09:20.519043+00:00","2021-07-27","614478","2022-02-01","Mr. Mario Hidalgo","2026-08-20T02:44:56.796+00:00","Via Express Delivery","2021-07-12",5,{"510k":128,"classification":129,"enforcement":130,"event":131,"event_backfill":132,"pma":133,"warning_letter":134},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]